尼日利亚临床局限性前列腺癌患者的护理质量和生存结果

IF 3 Q2 ONCOLOGY
JCO Global Oncology Pub Date : 2025-03-01 Epub Date: 2025-03-24 DOI:10.1200/GO-24-00504
Musliu Adetola Tolani, Christian Agbo Agbo, Alan Paciorek, Shehu Salihu Umar, Rufus Wale Ojewola, Faruk Mohammed, Ernie Kaninjing, Muhammed Ahmed, Rebecca DeBoer
{"title":"尼日利亚临床局限性前列腺癌患者的护理质量和生存结果","authors":"Musliu Adetola Tolani, Christian Agbo Agbo, Alan Paciorek, Shehu Salihu Umar, Rufus Wale Ojewola, Faruk Mohammed, Ernie Kaninjing, Muhammed Ahmed, Rebecca DeBoer","doi":"10.1200/GO-24-00504","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Optimal survival outcomes of prostate cancer are best achieved through high-quality care for curable disease. In Nigeria, various barriers may impede the curative treatment of prostate cancer, yet their impact on care and patient outcomes remains anecdotal. This study assessed treatment quality, survival outcomes, and interhospital differences of these metrics among patients with clinically localized prostate cancer in Nigeria.</p><p><strong>Methods: </strong>A retrospective study of patients with clinical stage T1-T3a, M0 prostate cancer at three tertiary hospitals in Nigeria over a 3-year period was conducted. Data on hospital sites, sociodemographics, clinicopathologic characteristics, quality metrics, imaging used, treatment, and survival status were collected. The primary end point was time from diagnosis to first treatment. Secondary end points were time from presentation to diagnosis, other prostate cancer quality metrics, all-cause survival, and interhospital differences in these metrics. Quality of diagnostics, treatments, and other outcomes were described and compared using Cox regression.</p><p><strong>Results: </strong>This study included 110 patients with a median age of 67 years. Most (n = 66, 61%) had high-risk disease. The median time from tertiary hospital presentation to diagnosis was 31 days. Median time from diagnosis to first treatment of any type was 68 days, with radical radiotherapy was 117 days, and with radical prostatectomy was 104 days. Eighteen percent (n = 20) had guideline-concordant imaging for tumor staging, 67 patients (61%) received any treatment or active surveillance, and retention in care was 42%. Three-year all-cause survival was 41%. There was a significant difference in most quality metrics including guideline-concordant imaging and treatment across the hospital sites.</p><p><strong>Conclusion: </strong>Time to treatment was delayed beyond international benchmarks; quality of staging, treatment, and care process were suboptimal; and survival was poor amid geographical disparities in care.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400504"},"PeriodicalIF":3.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12004982/pdf/","citationCount":"0","resultStr":"{\"title\":\"Quality of Care and Survival Outcomes Among Patients With Clinically Localized Prostate Cancer in Nigeria.\",\"authors\":\"Musliu Adetola Tolani, Christian Agbo Agbo, Alan Paciorek, Shehu Salihu Umar, Rufus Wale Ojewola, Faruk Mohammed, Ernie Kaninjing, Muhammed Ahmed, Rebecca DeBoer\",\"doi\":\"10.1200/GO-24-00504\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Optimal survival outcomes of prostate cancer are best achieved through high-quality care for curable disease. In Nigeria, various barriers may impede the curative treatment of prostate cancer, yet their impact on care and patient outcomes remains anecdotal. This study assessed treatment quality, survival outcomes, and interhospital differences of these metrics among patients with clinically localized prostate cancer in Nigeria.</p><p><strong>Methods: </strong>A retrospective study of patients with clinical stage T1-T3a, M0 prostate cancer at three tertiary hospitals in Nigeria over a 3-year period was conducted. Data on hospital sites, sociodemographics, clinicopathologic characteristics, quality metrics, imaging used, treatment, and survival status were collected. The primary end point was time from diagnosis to first treatment. Secondary end points were time from presentation to diagnosis, other prostate cancer quality metrics, all-cause survival, and interhospital differences in these metrics. Quality of diagnostics, treatments, and other outcomes were described and compared using Cox regression.</p><p><strong>Results: </strong>This study included 110 patients with a median age of 67 years. Most (n = 66, 61%) had high-risk disease. The median time from tertiary hospital presentation to diagnosis was 31 days. Median time from diagnosis to first treatment of any type was 68 days, with radical radiotherapy was 117 days, and with radical prostatectomy was 104 days. Eighteen percent (n = 20) had guideline-concordant imaging for tumor staging, 67 patients (61%) received any treatment or active surveillance, and retention in care was 42%. Three-year all-cause survival was 41%. There was a significant difference in most quality metrics including guideline-concordant imaging and treatment across the hospital sites.</p><p><strong>Conclusion: </strong>Time to treatment was delayed beyond international benchmarks; quality of staging, treatment, and care process were suboptimal; and survival was poor amid geographical disparities in care.</p>\",\"PeriodicalId\":14806,\"journal\":{\"name\":\"JCO Global Oncology\",\"volume\":\"11 \",\"pages\":\"e2400504\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12004982/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JCO Global Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1200/GO-24-00504\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO Global Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/GO-24-00504","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:通过对可治愈疾病的高质量护理,可获得最佳的前列腺癌生存结果。在尼日利亚,各种障碍可能阻碍前列腺癌的治愈性治疗,但它们对护理和患者预后的影响仍然是轶事。本研究评估了尼日利亚临床局限性前列腺癌患者的治疗质量、生存结果和这些指标的医院间差异。方法:回顾性分析尼日利亚三所三级医院临床分期T1-T3a、M0期前列腺癌患者3年的资料。收集了有关医院地点、社会人口统计学、临床病理特征、质量指标、影像学使用、治疗和生存状况的数据。主要终点为从诊断到首次治疗的时间。次要终点是从出现到诊断的时间,其他前列腺癌质量指标,全因生存,以及这些指标在医院间的差异。使用Cox回归对诊断、治疗和其他结果的质量进行描述和比较。结果:本研究纳入了110例患者,中位年龄为67岁。大多数(n = 66, 61%)有高危疾病。从三级医院就诊到诊断的中位时间为31天。从诊断到首次治疗的中位时间为68天,根治性放疗为117天,根治性前列腺切除术为104天。18% (n = 20)的患者接受了与指南一致的肿瘤分期成像,67名患者(61%)接受了任何治疗或积极监测,住院率为42%。3年全因生存率为41%。不同医院在大多数质量指标上存在显著差异,包括符合指南的成像和治疗。结论:治疗时间延迟超过国际基准;分期、治疗和护理过程的质量不理想;而且由于护理的地域差异,生存率很低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Quality of Care and Survival Outcomes Among Patients With Clinically Localized Prostate Cancer in Nigeria.

Purpose: Optimal survival outcomes of prostate cancer are best achieved through high-quality care for curable disease. In Nigeria, various barriers may impede the curative treatment of prostate cancer, yet their impact on care and patient outcomes remains anecdotal. This study assessed treatment quality, survival outcomes, and interhospital differences of these metrics among patients with clinically localized prostate cancer in Nigeria.

Methods: A retrospective study of patients with clinical stage T1-T3a, M0 prostate cancer at three tertiary hospitals in Nigeria over a 3-year period was conducted. Data on hospital sites, sociodemographics, clinicopathologic characteristics, quality metrics, imaging used, treatment, and survival status were collected. The primary end point was time from diagnosis to first treatment. Secondary end points were time from presentation to diagnosis, other prostate cancer quality metrics, all-cause survival, and interhospital differences in these metrics. Quality of diagnostics, treatments, and other outcomes were described and compared using Cox regression.

Results: This study included 110 patients with a median age of 67 years. Most (n = 66, 61%) had high-risk disease. The median time from tertiary hospital presentation to diagnosis was 31 days. Median time from diagnosis to first treatment of any type was 68 days, with radical radiotherapy was 117 days, and with radical prostatectomy was 104 days. Eighteen percent (n = 20) had guideline-concordant imaging for tumor staging, 67 patients (61%) received any treatment or active surveillance, and retention in care was 42%. Three-year all-cause survival was 41%. There was a significant difference in most quality metrics including guideline-concordant imaging and treatment across the hospital sites.

Conclusion: Time to treatment was delayed beyond international benchmarks; quality of staging, treatment, and care process were suboptimal; and survival was poor amid geographical disparities in care.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
JCO Global Oncology
JCO Global Oncology Medicine-Oncology
CiteScore
6.70
自引率
6.70%
发文量
310
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信